Recruiting

NGS-based Liquid Testing

Sponsor:

Glendale Adventist Medical Center d/b/a Adventist Health Glendale

Code:

NCT05703243

Conditions

Stage III Solid Tumors

Stage IV Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Comprehensive liquid molecular panel test

EORTC QLQ-30

Study Details

Brief summary:

To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive l i q u i d molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

Conditions

Stage III Solid Tumors

Stage IV Solid Tumors

Study ID

NCT05703243

Start date

Feb 1, 2023

Status verified date

Mar, 2023

Completion date

Jan 1, 2025

Anticipated

Primary completion date

Jan 1, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients who have given informed consent in accordance with the methods and procedures of this study
  • Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
  • Patients who have not received treatment related to his/her cancer
  • Patients who are willing to sign a release of medical records to the research team
  • Male and female patients ≥18 years of age
  • Patients under oncology care
  • Sufficient clinical status for collection of blood sample within usual care

Exclusion Criteria:

  • Patients considered minors in the jurisdiction where the protocol is conducted
  • Patients who are prisoners and pregnant women
  • Patients who cannot provide consent and did not sign a power of attorney

Study Design

Enrollment

572 participants

Anticipated

Interventions and Outcome Measures

Arms

Active

Newly diagnosed cancer patients.

Control

Historically diagnosed cancer patients.

Interventions

Comprehensive liquid molecular panel test

Lab test

EORTC QLQ-30

Quality of life questionnaire

Primary outcome measure

  • European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (QLQ-C30) [ Time Frame: 2 years ]

Central Contacts and Locations

Central contacts

Mihran H Shirinian, MD

818-543-7574mshirin@aol.com

Lily Villalobos, MHA

818-409-8009villall3@ah.org

Locations

Adventist Health Glendale

Recruiting

Glendale, California, United States, 91206

Contacts

Mihran Shirinian, M.D.

818-543-7574mshirin@aol.com

Principal Investigator:

Mihran Shirinian, M.D.

More Information

Sponsor

Glendale Adventist Medical Center d/b/a Adventist Health Glendale

Last update posted

Mar 3, 2023

Last verified

Mar, 2023

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Glendale Adventist Medical Center d/b/a Adventist Health Glendale on 2023-03-03.